Fludarabine Phosphate Suppliers & Bulk Manufacturers
Available Forms: Injection (IV), Oral Tablet
Available Strengths: Injection: 25 mg/ml; Tablet: 10 mg
Reference Brands: Fludara® (US & EU)
Category:
Oncology Cancer Care
Fludarabine Phosphate is an oncology drug used to treat CLL and blood cancers. Available as a 25 mg/mL IV injection and 10 mg tablets in the US and EU.
Fludarabine Phosphate is available in Injection (IV), Oral Tablet
and strengths such as Injection: 25 mg/ml; Tablet: 10 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Fludarabine Phosphate is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Fludarabine Phosphate can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Fludarabine Phosphate is a widely used oncology medication indicated for chronic lymphocytic leukemia (CLL) and certain non-Hodgkin’s lymphomas. It is available in the US and EU as a 25 mg/mL injection and 10 mg oral tablets. Marketed under the brand name Fludara® and as generics, Fludarabine Phosphate is a purine analog that interferes with DNA synthesis, promoting apoptosis in malignant cells. It is a critical chemotherapy option in hematologic cancer protocols and widely used in hospital oncology units and pharma B2B distribution. Its established efficacy and regulatory approval make it a trusted choice across global markets.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing